Tibotec News
 25 November 2009 - U.S. Food and Drug Administration (FDA) Grants Traditional Approval for
INTELENCE® (Etravirine)
Read more...
12 November 2009 - Once Daily PREZISTA® (darunavir) Monotherapy Shows Similar Efficacy and Safety as Combination Therapy
48-week monotherapy data presented at the 2009 European AIDS Society Conference
Read more...
31 October 2009 - More than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response wtih Twice-Daily Telaprevir-Based Regimen
Phase II telaprevir data from Tibotec featured in oral presentation at AASLD
Read more...
21 July 2009 - Study Shows PREZISTA®-Based HIV Therapy May Improve Immune Cell Function in Treatment Experienced Patients
Data presented from GRACE immunology substudy
Read more...
20 July 2009 - New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies
GRACE compares efficacy and safety of PREZISTA/ritonavir in treatment-experienced women vs. men at 48 weeks
Read more...
20 July 2009 - 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM)
(Etravirine) As Part of HIV Combination Therapy
Read more...
16 July 2009 - Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 And Truvada® With Gilead Sciences
Product Could Represent a New, Once-Daily Antiretroviral Treatment Option
Read more...
17 June 2009 - Unique Collaboration Between TB Alliance and Tibotec to Accelerate Tuberculosis Drug Development
Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis
Read more...
03 June 2009 - Data on Investigational Drug TMC207 For Treatment of MDR-Tuberculosis, Published in the New England Journal of Medicine
Clinical Activity Of TMC207 shows ATP-Synthase is a Viable Target for treatment of TB
Read more...
24 April 2009 - New Data on Tibotec Investigational Hepatitic C Compounds being Presented at EASL
Tibotec antivirals take new approach to treating HCV
Read more...
|
